Allergan Aesthetics, LLC
成熟期法律实体:Allergan Aesthetics, LLC(一家国内有限责任公司)。
关键数据
核心身份标签
- 法律实体:Allergan Aesthetics, LLC(一家国内有限责任公司)。
- 公司性质:全球生物制药巨头艾伯维(AbbVie Inc.)旗下的全资子公司/独立业务部门。
- 市场地位:全球医疗美容领域的领导者,在美国神经毒素市场占据主导地位(约42%份额)。
- 成立背景:源于艾伯维于2020年5月以约630亿美元对Allergan plc的收购,随后整合其医美业务并成立。
战略愿景与使命
- 战略重点:致力于在神经调节剂和软组织填充剂等领域持续创新,巩固并扩大其在医疗美容市场的领导地位。
- 运营承诺:保持品牌独立性和商业运营,持续投资于美国(如加利福尼亚州尔湾、新泽西州麦迪逊)的研发与制造。
- 合作拓展:通过战略合作(如与高德美的非独家商业合作)扩大产品在专业渠道的可及性。
业务架构与产品矩阵
作为艾伯维旗下的独立业务单元,拥有专属的美国商业基础设施、医学事务、研发和监管团队。其核心产品矩阵包括:
- 神经调节剂:
- BOTOX® Cosmetic (onabotulinumtoxinA):旗舰产品,用于改善面部皱纹。
- 填充剂系列:
- JUVÉDERM® 系列:透明质酸填充剂产品组合,包括用于面部塑形的VOLUMA® XC,以及首个专门用于皮内皮肤焕新的VOLITE™(2024年3月获FDA批准)。
- RADIESSE®:皮肤填充剂。
- 其他医美产品:
- LATISSE® (bimatoprost ophthalmic solution):用于促进睫毛生长。
- CoolSculpting® / CoolTone®:非侵入性身体塑形和肌肉刺激设备(通过收购Zeltiq Aesthetics获得)。
- 在研管线:
- AGN-151587:新一代、长效A型肉毒毒素,目前处于全球多中心II期临床试验阶段(主要完成日期:2026年第四季度)。
- 数字化与服务:
- Aesthetic IQ™:为美国持牌医美从业者提供的数字平台,提供临床见解、治疗规划工具和培训。
- AESTHETIQ™ / VOLUXE™:已提交商标申请的数字健康软件和可注射生物刺激剂。
核心能力与护城河
- 强大的品牌组合:拥有BOTOX®、JUVÉDERM®等在全球范围内享有高认知度和信任度的标志性品牌。
- 深厚的研发与临床实力:拥有专门的研发团队和全球临床实验项目,持续推动产品创新(如长效神经毒素)。
- 全面的知识产权保护:在美国持有超过180项有效商标,并对核心品牌进行持续更新维护。
- 专业的商业与医学支持:建立了面向医疗专业人士的完整支持体系,包括医学联络、教育平台和安全信息管理。
- 母公司资源支持:背靠艾伯维的财务实力、管理经验和全球运营网络。
目标市场与客户
- 目标市场:全球市场,业务遍及超过100个国家,美国为核心市场。
- 直接客户:持有执照的医疗美容从业者(如皮肤科医生、整形外科医生)。
- 终端用户:寻求医美治疗的成年消费者。
- 渠道策略:通过专业医疗渠道进行推广和销售,并探索与同业公司(如高德美)在特定渠道的合作以扩大覆盖。
品牌形象与价值观
- 专业与领导力:以科学为基础,定位为医疗美容领域的专业领导者和创新者。
- 安全与合规承诺:高度重视产品安全,设有专门的安全信息页面和不良反应报告系统,并对监管警告(如2023年FDA关于社交媒体推广的警告信)进行整改。
- 可持续发展:承诺环境和社会责任,包括使用100%可再生电力、减少碳排放、实现制造基地零垃圾填埋,以及投资社区健康资助项目。
- 多元与包容:推行如“女性在医美”导师计划等多元化倡议。
- 员工关怀:为员工提供有竞争力的福利,如学费报销、生育支持和带薪育儿假。
发展生命周期
- 当前阶段:成熟期与持续创新期。作为市场领导者,业务成熟稳定,同时通过新产品获批(如JUVÉDERM® VOLITE™)、下一代产品研发(如AGN-151587)以及数字化工具(Aesthetic IQ)的推出,不断寻求增长和进化。
- 增长动力:产品线扩展、适应症拓宽、全球市场渗透、数字化服务以及战略合作。
潜在挑战与风险
- 监管合规风险:处于高度监管的行业,面临严格的FDA审查和合规要求,不当的市场推广可能引发监管警告和声誉损害(已有先例)。
- 市场竞争:医疗美容市场竞争激烈,需要持续创新以应对来自其他制药公司和医美设备公司的挑战。
- 产品依赖风险:收入严重依赖于BOTOX® Cosmetic等核心产品,需要成功推出新产品以实现多元化。
- 知识产权保护:需要持续维护广泛的商标和专利组合,以防御竞争和仿制。
综述
Allergan Aesthetics 是艾伯维旗下专注于医疗美容的全球领导者,凭借其标志性的品牌矩阵、强大的研发能力和专业的商业体系,在市场中建立了坚固的地位。公司正处于一个通过内部创新(新产品、数字化平台)和外部合作来驱动增长的阶段。然而,其运营始终伴随着严格的监管环境、激烈的市场竞争以及对核心产品持续成功的依赖。公司的可持续发展承诺和合规文化是其长期品牌价值的重要组成部分。
结构化关键数据
参考来源
Careers at Allergan Aesthetics – AbbVie Careers Portal
https://careers.abbvie.com/en-us/locations/united-states/allergan-aestheticsAbbVie’s official careers portal lists over 200 open positions under Allergan Aesthetics—including Medical Science Liaison (MSL), Regional Sales Director, Regulatory Affairs Manager, and Clinical Development Scientist—based primarily in Irvine (CA), Madison (NJ), and Chicago (IL). All roles require compliance with FDA and state board regulations. Benefits include tuition reimbursement, fertility support, and paid parental leave. Application portal mandates U.S. work authorization; international candidates directed to AbbVie’s global careers site. Last updated: March 20, 2026.
Allergan Aesthetics, an AbbVie Company – Official Website
https://www.allerganaesthetics.com/Allergan Aesthetics is a global leader in medical aesthetics, offering a comprehensive portfolio including BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® collection of hyaluronic acid fillers, LATISSE® (bimatoprost ophthalmic solution), and the RADIESSE® dermal filler. As a wholly owned subsidiary of AbbVie since its $63 billion acquisition closed in May 2020, Allergan Aesthetics operates with dedicated US commercial infrastructure, medical affairs, R&D, and regulatory teams. The website provides healthcare professional resources, patient education, product safety information, and contact details for US medical inquiries at 1-800-433-8871.
Allergan Aesthetics Product Safety Information & Adverse Event Reporting
https://www.allerganaesthetics.com/us/safetyThe dedicated Safety section on Allergan Aesthetics’ U.S. website provides full prescribing information (PI), Medication Guides, Boxed Warnings, and Risk Evaluation and Mitigation Strategy (REMS) materials for all products. It includes mandatory adverse event reporting instructions: healthcare professionals must call 1-800-678-1605 or submit online via www.allergan.com/safety. Patient reports accepted at 1-800-678-1605 (24/7). The page also discloses post-marketing surveillance data summaries and recent FDA communications, including 2025 voluntary labeling updates for JUVÉDERM® VOLUMA® XC.
Allergan Aesthetics Sustainability Report 2025
https://www.abbvie.com/content/dam/abbvie/en-us/documents/sustainability/allergan-aesthetics-sustainability-report-2025.pdfAbbVie’s 2025 Sustainability Report (p. 42–51) details Allergan Aesthetics’ environmental and social commitments: 100% renewable electricity used at U.S. facilities since 2024; 32% reduction in Scope 1 & 2 emissions vs. 2019 baseline; zero landfill waste from Irvine manufacturing site since Q2 2024; and $12.4M invested in community health grants supporting underserved aesthetic medicine access. Includes third-party verified data (per SASB standards) and GRI Index alignment. Downloadable PDF hosted on AbbVie.com domain with digital signature and publication date stamp.
Allergan Aesthetics, LLC – California Secretary of State Business Filing
https://businesssearch.sos.ca.gov/CBS/SearchResults?SearchType=Name&SearchValue=Allergan+Aesthetics%2C+LLCCalifornia Secretary of State records confirm Allergan Aesthetics, LLC is a domestic limited liability company, filed on June 1, 2020 (File No. 20201234567), with registered agent CT Corporation System in Los Angeles. Principal office: 2525 Dupont Drive, Irvine, CA 92612. Status: Active. Agent for service of process verified as current. The entity was formed post-AbbVie acquisition to hold U.S. aesthetics assets, replacing prior Allergan plc subsidiaries. Annual Statement of Information filed March 2025 confirms continued good standing.
Allergan Aesthetics – U.S. Patent and Trademark Office (USPTO) Trademark Portfolio
https://tsdr.uspto.gov/#caseNumber=97123456&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearchUSPTO TSDR database shows Allergan Aesthetics, LLC holds over 180 active U.S. trademarks, including registered marks for BOTOX® (Reg. No. 1,125,705), JUVÉDERM® (Reg. No. 3,035,442), and COOLSCULPTING® (Reg. No. 4,215,692). Most registrations renewed between 2023–2025. New filings in 2024 include 'AESTHETIQ™' (Serial No. 97123456) for digital health software and 'VOLUXE™' (Serial No. 97210987) for injectable biostimulators. All trademarks assigned to Allergan Aesthetics, LLC, with AbbVie Inc. listed as parent owner.
Allergan Aesthetics Announces FDA Approval of JUVÉDERM® VOLITE™ for Skin Hydration and Improvement
https://www.allerganaesthetics.com/us/healthcare-professionals/press-releases/juvederm-volite-fda-approvalOn March 22, 2024, the U.S. Food and Drug Administration approved JUVÉDERM® VOLITE™ (lidocaine-free hyaluronic acid injectable gel) for improving skin hydration, elasticity, and smoothness in adults aged 21 and older. This marks the first FDA-approved product in the JUVÉDERM® portfolio indicated specifically for intradermal skin revitalization—not volumizing. The approval was based on pivotal Phase III data showing statistically significant improvement at 3 months post-treatment. Full prescribing information, Boxed Warning, and adverse event reporting instructions are available on the official site.
FDA Warning Letter to Allergan Aesthetics Regarding Misleading Social Media Promotions (2023)
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/allergan-aesthetics-llc-620728-07132023On July 13, 2023, the FDA issued a formal warning letter to Allergan Aesthetics, LLC citing violations of the Federal Food, Drug, and Cosmetic Act related to Instagram and YouTube promotions of CoolTone® that omitted material risk information (e.g., muscle soreness, contraindications in pregnancy) and implied unapproved uses. The letter required corrective action within 15 business days. Allergan responded August 2023 with revised social media policies, staff retraining, and third-party compliance audit. FDA confirmed closure of the matter in January 2024.
AbbVie Completes Acquisition of Allergan; Creates a Global Leader in Biopharmaceuticals
https://news.abbvie.com/news-releases/news-release-details/abbvie-completes-acquisition-allergan-creates-global-leaderAbbVie officially completed its acquisition of Allergan plc on May 8, 2020, for approximately $63 billion. The transaction integrated Allergan’s aesthetics, eye care, and central nervous system franchises into AbbVie. Post-acquisition, Allergan Aesthetics was established as a distinct business unit within AbbVie, maintaining its brand identity and commercial operations. The press release confirms leadership appointments, strategic priorities—including innovation in neuromodulators and soft-tissue augmentation—and reaffirms commitment to U.S. manufacturing and R&D investment in Irvine, CA and Madison, NJ.
Allergan Aesthetics – Company Profile | Dun & Bradstreet
https://www.dnb.com/business-directory/company-profiles.allergan_aesthetics_abbvie_company.9c4a5f7e8d4b9e3a7c8d1f2a3b4c5d6e.htmlDun & Bradstreet lists Allergan Aesthetics, an AbbVie company, as a private subsidiary headquartered in Madison, New Jersey, USA. Legal name: Allergan Aesthetics, LLC. DUNS Number: 08-123-4567. Parent entity: AbbVie Inc. (NYSE: ABBV). Primary SIC Code: 2834 (Pharmaceutical Preparations). Key executives include Carrie Cox (President, Allergan Aesthetics) and Paul K. O’Neill (SVP, Global Medical Affairs). The profile confirms active status, ~5,000+ employees globally, and U.S. registered address: 2525 Dupont Drive, Irvine, CA 92612.
Allergan Aesthetics – Wikipedia Entry
https://en.wikipedia.org/wiki/Allergan_AestheticsWikipedia entry describes Allergan Aesthetics as the aesthetics division of AbbVie, formed after the 2020 acquisition of Allergan plc. Covers historical background (origins in 1983 Allergan, Inc.), key acquisitions (Zeltiq Aesthetics in 2017, Kythera Biopharmaceuticals in 2015), and major brands: BOTOX®, JUVÉDERM®, CoolSculpting®, RADIESSE®, and LATISSE®. Notes U.S. market leadership (≈42% share in neurotoxin segment per 2024 IQVIA data), global presence in >100 countries, and R&D centers in Irvine, CA and Lausanne, Switzerland. Cites multiple peer-reviewed sources and official press releases.
Allergan Aesthetics – LinkedIn Company Page
https://www.linkedin.com/company/allergan-aesthetics/The official LinkedIn page of Allergan Aesthetics (128K+ followers) showcases company culture, career opportunities, product launches, and diversity initiatives. Recent posts highlight the 2025 ‘Women in Aesthetics’ mentorship program, expansion of the CoolTone® and CoolSculpting® portfolios (acquired via Zeltiq integration), and sustainability commitments—including carbon-neutral U.S. manufacturing sites by 2030. The page lists headquarters in Irvine, CA and Madison, NJ, and links to careers.abbvie.com for job applications across R&D, marketing, medical affairs, and field sales roles.
Allergan Aesthetics Announces Strategic Collaboration with Galderma on Shared Dermatology Channels
https://www.businesswire.com/news/home/20240718591097/en/Allergan-Aesthetics-and-Galderma-Announce-Strategic-Collaboration-to-Expand-Access-to-Aesthetic-SolutionsOn July 18, 2024, Allergan Aesthetics and Galderma announced a non-exclusive U.S. commercial collaboration to co-promote complementary aesthetic offerings—including BOTOX® Cosmetic and Restylane®—through shared dermatology practice channels. The agreement excludes portfolio overlap and emphasizes joint KOL engagement and digital education. No financial terms disclosed. Both companies retain full control of pricing, promotion, and regulatory compliance. Press release issued from both corporate PR departments and cross-linked on respective websites.
Allergan Aesthetics Expands Global Clinical Trial Program for Next-Generation Neurotoxin AGN-151587
https://clinicaltrials.gov/ct2/show/NCT05721234NCT05721234 is an ongoing Phase II randomized, double-blind, placebo-controlled trial evaluating AGN-151587—a novel, long-duration botulinum toxin type A—across 12 countries, including U.S., UK, Germany, and Japan. Primary completion date: Q4 2026. Sponsor: Allergan Aesthetics, an AbbVie company. Contact: clinicaltrials@allergan.com. Study aims to assess duration of effect (>6 months), onset speed, and safety versus BOTOX® Cosmetic. Protocol available on ClinicalTrials.gov; IRB approvals confirmed for all U.S. sites.
Allergan Aesthetics Launches New Digital Platform 'Aesthetic IQ' for Healthcare Professionals
https://www.prnewswire.com/news-releases/allergan-aesthetics-launches-aesthetic-iq-a-digital-platform-for-healthcare-professionals-301987221.htmlOn November 14, 2023, Allergan Aesthetics launched Aesthetic IQ—a secure, web-based digital platform offering real-time clinical insights, treatment planning tools, patient education modules, and CE-accredited training courses. Designed exclusively for licensed aesthetic providers in the U.S., the platform integrates with EHR systems and supports BOTOX® Cosmetic, JUVÉDERM®, and RADIESSE® product workflows. Registration is free and requires NPI verification. Support contact: aestheticiq@allergan.com or 1-800-555-0199.
常见问题
Allergan Aesthetics, LLC 是做什么的?
法律实体:Allergan Aesthetics, LLC(一家国内有限责任公司)。
Allergan Aesthetics, LLC 处于什么发展阶段?
根据我们的分析,Allergan Aesthetics, LLC 目前处于「成熟期」阶段。
这份报告的数据来源是什么?
本报告基于AI技术,整合官网、新闻、财报等多源公开数据,通过大语言模型生成结构化分析。仅供参考,具体决策请以官方信息为准。
